NeuroOne Medical Technologies Corporation (NMTC) Key Metrics
NMTC valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $8.8M
- Enterprise value
- $10.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 0.7 10-yr median 8.0
- Price / book
- 3.3 10-yr median 3.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.76
NMTC key metrics, FY2016–FY2025
Fiscal year ended September 30, 2025 · U.S. dollarsNMTC valuation Price multiples at each fiscal year-end price.
Price / sales−61.6%
2.9
FY2025 · hover or tap a bar for each year
FY2016FY2025
Price / book−84.3%
5.0
FY2025 · hover or tap a bar for each year
FY2016FY2025
Free cash flow yield+33.8 pts
−8.2%
FY2025 · hover or tap a bar for each year
FY2016FY2025
NMTC returns How much profit the business earns on the capital it uses.
Return on equity+257.1 pts
−91.3%
FY2025 · hover or tap a bar for each year
FY2016FY2025
Return on assets+138.3 pts
−44.6%
FY2025 · hover or tap a bar for each year
FY2016FY2025
Free cash flow margin+298.3 pts
−24.1%
FY2025 · hover or tap a bar for each year
FY2016FY2025
Asset turnover+192.1%
1.50
FY2025 · hover or tap a bar for each year
FY2016FY2025
NMTC per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+133.5%
$1.81
FY2025 · hover or tap a bar for each year
FY2016FY2025
Earnings per share
−$0.54
FY2025 · hover or tap a bar for each year
FY2016FY2025
Free cash flow per share
−$0.44
FY2025 · hover or tap a bar for each year
FY2016FY2025
Book value per share+473.5%
$1.06
FY2025 · hover or tap a bar for each year
FY2016FY2025
Shares outstanding+50.0%
6.7M
FY2025 · hover or tap a bar for each year
FY2016FY2025
NMTC financial health Debt, liquidity and how easily interest is covered.
Debt / equity−88.1%
0.04
FY2025 · hover or tap a bar for each year
FY2016FY2025
Net debt−$5.1M
−$6.3M
FY2025 · hover or tap a bar for each year
FY2016FY2025
Current ratio+112.2%
4.44
FY2025 · hover or tap a bar for each year
FY2016FY2025
Interest coverage
-12.7
FY2025 · hover or tap a bar for each year
FY2016FY2025
Debt / assets−48.9%
0.02
FY2025 · hover or tap a bar for each year
FY2016FY2025
NMTC efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+12 days
22 days
FY2025 · hover or tap a bar for each year
FY2016FY2025
Days of inventory−111 days
224 days
FY2025 · hover or tap a bar for each year
FY2016FY2025
Days payables outstanding−38 days
94 days
FY2025 · hover or tap a bar for each year
FY2016FY2025
Cash conversion cycle−61 days
152 days
FY2025 · hover or tap a bar for each year
FY2016FY2025
Capex / revenue−2.8 pts
0.7%
FY2025 · hover or tap a bar for each year
FY2016FY2025
NMTC valuation history
Fiscal year-endToday10-year median
NMTC returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NMTC debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NMTC cash returned to shareholders
DividendsBuybacksFree cash flow
NMTC price vs earnings per share
Share price at year-endEPS (right axis)
NMTC key metrics
FY2016–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $35.7M | $26.5M | $16.1M | $27.0M | — | — | — | — | — | — |
| Enterprise value | $29.4M | $25.3M | $11.0M | $16.1M | — | — | — | — | — | — |
| Price / sales | 2.9 | 7.7 | 8.3 | 158.0 | — | — | — | — | — | — |
| Price / book | 5.0 | 32.2 | 2.6 | 2.8 | — | — | — | — | — | — |
| EV / sales | 2.4 | 7.3 | 5.6 | 94.1 | — | — | — | — | — | — |
| Earnings yield | −10.1% | −46.5% | −73.5% | −37.0% | — | — | — | — | — | — |
| Free cash flow yield | −8.2% | −42.0% | −82.2% | −28.8% | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.3% | 0.3% | 0.7% | 0.0% | — | — | — | — | — | — |
| Share price at fiscal year-end | $5.33 | $5.94 | $5.34 | $10.14 | $23.70 | $23.13 | $33.66 | $81.00 | $63.00 | — |
| Per share | ||||||||||
| Revenue per share | $1.81 | $0.77 | $0.65 | $0.06 | — | — | — | — | — | — |
| Earnings per share | −$0.54 | −$2.76 | −$3.93 | −$3.75 | — | — | — | — | — | — |
| Operating cash flow per share | −$0.42 | −$2.47 | −$4.27 | −$2.82 | — | — | — | — | — | — |
| Free cash flow per share | −$0.44 | −$2.50 | −$4.39 | −$2.92 | — | — | — | — | — | — |
| Cash per share | $0.98 | $0.33 | $1.76 | $4.18 | — | — | — | — | — | — |
| Book value per share | $1.06 | $0.18 | $2.07 | $3.60 | — | — | — | — | — | — |
| Tangible book value per share | $1.05 | $0.17 | $2.04 | $3.56 | — | — | — | — | — | — |
| Capex per share | $0.01 | $0.03 | $0.13 | $0.10 | — | — | — | — | — | — |
| Debt per share | $0.04 | $0.06 | $0.06 | $0.08 | — | — | — | — | — | — |
| Shares outstanding | 6.7M | 4.5M | 3.0M | 2.7M | — | — | — | — | — | — |
| Change in shares outstanding | +50.0% | +47.7% | +13.3% | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −91.3% | −348.4% | −149.6% | −123.8% | −230.8% | — | — | — | — | — |
| Return on assets (ROA) | −44.6% | −182.9% | −113.4% | −96.3% | −156.7% | −515.5% | — | — | −12.6% | — |
| Return on tangible assets | −33.6% | −232.3% | −148.1% | −78.7% | −127.5% | −296.3% | — | — | −8.3% | — |
| Free cash flow margin | −24.1% | −322.4% | −679.7% | — | — | −184.1% | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $266,806 | $260,160 | $184,400 | $202,895 | $315,673 | $1.3M | — | $1.7M | $275,197 | $13,619 |
| Cash & short-term investments | $6.6M | $1.5M | $5.3M | $11.1M | $6.9M | $4.0M | $260,749 | $13,260 | $522,217 | −$1,838 |
| Net debt | −$6.3M | −$1.2M | −$5.1M | −$10.9M | −$6.6M | −$2.7M | −$260,749 | $1.7M | −$247,020 | $15,457 |
| Debt / equity | 0.04 | 0.32 | 0.03 | 0.02 | 0.05 | 0.64 | — | — | — | — |
| Debt / assets | 0.02 | 0.05 | 0.02 | 0.02 | 0.04 | 0.28 | — | 7.67 | 0.36 | 7.41 |
| Current ratio | 4.44 | 2.09 | 4.08 | 3.93 | 6.17 | 1.76 | 0.17 | 0.00 | 0.85 | 0.02 |
| Quick ratio | 3.47 | 0.90 | 3.12 | 3.70 | 6.09 | 1.76 | 0.17 | 0.00 | 0.85 | 0.02 |
| Interest coverage | -12.7 | -51.9 | — | -322.0 | — | -0.7 | -20.4 | -2.3 | — | -2.2 |
| Working capital | $7.9M | $2.4M | $5.5M | $9.1M | $6.1M | $1.8M | −$1.5M | −$3.8M | −$101,150 | −$81,492 |
| Invested capital | $768,946 | −$377,869 | $1.1M | −$1.3M | −$31,772 | −$650,843 | −$1.5M | −$2.7M | −$513,240 | −$66,035 |
| Tangible asset value | $7.0M | $754,751 | $6.2M | $9.5M | $6.4M | $1.9M | −$1.4M | −$4.6M | −$447,110 | −$181,785 |
| Net current asset value | $6.5M | $82,998 | $5.5M | $9.0M | $5.9M | $1.5M | −$1.5M | −$4.6M | −$447,110 | −$81,492 |
| Graham net-net per share | $0.74 | −$0.37 | $1.44 | $3.11 | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Share buybacks (net) | $124,617 | $81,403 | $119,419 | $0 | — | — | — | $0 | $0 | $0 |
| Capex / revenue | 0.7% | 3.5% | 19.7% | 160.8% | 37.7% | 6.4% | — | — | — | 7,864.2% |
| Capex / depreciation | 0.31 | 0.49 | 1.93 | 2.32 | 0.83 | 2.57 | 4.47 | 4.23 | 11.85 | 7.51 |
| Stock-based compensation / revenue | 10.5% | 38.9% | 56.6% | 553.4% | 1,006.6% | 95.3% | — | — | — | — |
| R&D / revenue | 41.2% | 146.7% | 355.5% | 2,879.9% | 2,203.3% | 107.7% | — | — | — | 99,101.5% |
| SG&A / revenue | 61.0% | 228.8% | 345.9% | 3,919.4% | 3,514.1% | 246.7% | — | — | — | 6,682.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 21.7 | 9.3 | 3.1 | 87.0 | 49.5 | 0.0 | — | — | — | — |
| Days of inventory on hand | 224.3 | 335.4 | 296.6 | 605.5 | 65.0 | — | — | — | — | — |
| Days payables outstanding | 94.1 | 131.8 | 196.8 | 1,098.6 | 854.2 | 4,953.6 | 9,093.6 | 2,051.8 | 783.3 | — |
| Cash conversion cycle (days) | 151.9 | 212.9 | 103.0 | -406.1 | -739.7 | -4,953.6 | — | — | — | — |
| Receivables turnover | 16.79 | 39.10 | 117.49 | 4.20 | 7.37 | — | — | — | — | — |
| Payables turnover | 3.88 | 2.77 | 1.86 | 0.33 | 0.43 | 0.07 | 0.04 | 0.18 | 0.47 | 0.00 |
| Inventory turnover | 1.63 | 1.09 | 1.23 | 0.60 | 5.61 | — | — | — | — | — |
| Asset turnover | 1.50 | 0.51 | 0.19 | 0.02 | 0.03 | 0.73 | 0.00 | 0.00 | 0.00 | 0.73 |
| Average receivables | $720,720 | $88,318 | $16,618 | $40,786 | $24,168 | $0 | — | — | — | — |
| Average payables | $1.0M | $857,155 | $806,383 | $728,246 | $645,684 | $957,505 | $686,854 | $121,798 | $16,610 | $10,412 |
| Average inventory | $2.4M | $2.2M | $1.2M | $401,412 | $49,144 | $0 | — | $0 | $0 | $0 |
| Intangibles / total assets | 0.4% | 1.3% | 1.1% | 0.9% | 1.7% | 3.3% | 33.6% | 91.5% | 23.9% | 5,456.6% |
Computed from NMTC's annual financial statements (latest annual report filed December 17, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NMTC valuation and financial ratios
NeuroOne Medical Technologies earned a return on equity of −91.3% in fiscal 2025. It ended the year with $0.3 million of debt and $6.6 million in cash and short-term investments, a net cash position of $6.3 million. It returned $0.1 million to shareholders: $0 in dividends and $0.1 million in share buybacks.
See the NMTC income statement, the NMTC chart for price history, or the NMTC stock overview for the latest quote and news.
NMTC key metrics FAQ
What is NeuroOne Medical Technologies's return on equity?
NeuroOne Medical Technologies's return on equity (ROE) was −91.3% in fiscal 2025: net income of -$3.6 million on average shareholders' equity of $3.9 million.
How much debt does NeuroOne Medical Technologies have?
NeuroOne Medical Technologies had total debt of $0.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.04 and more cash than debt.
Does NeuroOne Medical Technologies buy back its shares?
Yes. NeuroOne Medical Technologies spent $0.1 million on net share repurchases in fiscal 2025 Shares outstanding changed +50.0% over the year, to 6.7M..
What is NeuroOne Medical Technologies's free cash flow yield?
NeuroOne Medical Technologies generated -$2.9 million of free cash flow in fiscal 2025, a free cash flow yield of −8.2% on its market value at year-end ($35.7 million).
What is NeuroOne Medical Technologies's current ratio?
NeuroOne Medical Technologies's current ratio was 4.44 at the end of fiscal 2025: current assets were 4.44 times current liabilities.